In-licensed technologies for the development of therapeutics for the treatment and prevention of autoimmune diabetes



The GAD-based diabetes vaccine Diamyd® is considered the world’s furthest developed Antigen Based Therapy (ABT) for treating autoimmune diabetes


GABA combined with Antigen Based Therapy (ABT) in preclinical type 1 diabetes studies has shown synergistically improved results and may have applications in many inflammatory disorders


Gliadin has shown promising effects in reducing and delaying the onset of hyperglycemia in preclinical type 1 diabetes studies

Combining Technologies

Type 1 diabetes is a complex disease. The dominating hypothesis among diabetes researchers today is that the key to curing type 1 diabetes is to simultaneously tackle the disease on several fronts by combining various therapeutics or by providing treatment before onset of the disease. Antigen Based Therapy (ABT) is considered of importance for treating the disease.

The development of the in-licensed technologies for GAD, GABA and Gliadin, in combination or with other substances with various mechanisms of action, is carried out in preclinical studies and clinical trials.



Pre-clinical and clinical development projects with novel dosing strategies and combinations using GAD, GABA, Gliadin and other immunomodulatory agents.


GAD, the active ingredient in the diabetes vaccine Diamyd®, is an endogenous human enzyme which catalyzes the synthesis of GABA from glutamic acid. GAD is well known to be expressed in nerve cells, but also in beta cells, where its role is not yet fully understood. It is clear, however, that GAD is one of the most important autoantigens involved in the degenerative autoimmune process directed against the beta cells in type 1 diabetes.

Antigen Based Therapy using Diamyd® is intended to halt the destruction of beta cells by the immune system in type 1 diabetes and LADA by inducing tolerance to autoantigens. The therapy has been studied in clinical trials with over 1,000 patients.

By combining Diamyd® with other anti-inflammatory or immunosuppressive compounds, initiating treatment earlier or by alternative administration routes, the efficacy of the therapy can be enhanced.

Diamyd®, the Antigen Based Therapy, is the Company’s furthest developed project. Six clinical trials are currently ongoing evaluating the diabetes vaccine Diamyd® through alternative approaches with various immunomodulatory compounds, including a combination treatment with GABA.

Diamyd Medical licenses exclusive rights to GAD, the active component of the therapy, from UCLA for the treatment of type 1 diabetes for which the last patent expires in 2032.

GABA, or gamma-aminobutyric acid, is synthesized from the amino acid glutamate in cells by the enzyme GAD. It is a well-known inhibitory neurotransmitter, but it also plays a key role in the regulation of metabolism and the immune system. It is produced in many peripheral tissues including the insulin-producing beta cells of the pancreas, and cellular surface receptors for the molecule are found on cells of the immune system.

Ingestion of GABA has been shown to synergistically enhance the effect of Antigen Based Therapy in type 1 diabetes animal models. It has also been shown to increase the proliferation and decrease apoptosis of transplanted human beta cells in association with increased serum insulin levels and a decrease in serum glucagon. GABA also decreased blood sugar levels and improved glucose homeostasis.

It is anticipated that GABA can be used in the general treatment of autoimmune and inflammatory disorders such as type 2 diabetes, rheumatoid arthritis and metabolic syndrome.

GABA is being administered in an ongoing placebo-controlled clinical study in Birmingham (Alabama, USA) in combination with the diabetes vaccine Diamyd®. Diamyd Medical licenses exclusive rights to use GABA for the treatment of diabetes and other inflammatory disorders.

Gliadin is a component of gluten protein found in wheat and several other cereals. It is the major antigen involved in celiac disease. Celiac disease and type 1 diabetes share the same genetic high risk group, and the proportion of people with diabetes with celiac disease is 8 percent compared to 1 percent in the general population.

Intranasally-administered Gliadin has been shown to significantly delay the onset and decrease the incidence of hyperglycemia in a type 1 diabetes animal model. It is anticipated that the effects of Gliadin therapy on the mucosal immune system will lead to improved functionality and survival of the insulin-producing beta cells.

Gliadin also has potential as an active component in the treatment of celiac disease and Inflammatory bowel disease. In combination with Diamyd Medical’s other patented technologies, such as GABA, Gliadin therapy may be enhanced.

Diamyd Medical intends to evaluate combination therapies with Gliadin and other compounds such as GABA in type 1 diabetes, celiac disease and other inflammatory disorders. Diamyd Medical exclusively licenses rights to Gliadin for the treatment and prevention of type 1 diabetes.



Diamyd® is a GAD-based diabetes vaccine aiming to stop or delay the autoimmune process by inducing tolerance to GAD, one of the major autoantigens in autoimmune diabetes



A candidate drug passes a number of development stages. Parallel to the discovery, preclinical and clinical phases, a commercially viable manufacturing process must be secured to obtain future market approval.

GMP Production

Diamyd Medical’s diabetes vaccine is produced via an established manufacturing process
and is approved for testing in children in clinical trials


GMP Manufacturing Process

Drug manufacturing is controlled by a strict regulatory framework called Good Manufacturing Practice (GMP), which sets high quality standards. Production of biologics requires complex technology and a stable manufacturing process. Diamyd Medical’s GMP production of the recombinant GAD protein has been subject to rigorous development work in collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), resulting in a biologics manufacturing process prepared for commercial launch.

Recombinant GAD Protein

Diamyd Medical's recombinant protein GAD (rhGAD65), the active ingredient in the diabetes vaccine Diamyd®, is manufactured by the US vaccine development and protein production company Protein Sciences Corporation. Protein Sciences is manufacturing GMP recombinant GAD protein using Protein Sciences’ proprietary Baculovirus Expression Vector System (BEVS) technology for Diamyd Medical’s upcoming late stage clinical trials for autoimmune diabetes.

Antigen Based Therapy with Diamyd®

GAD is one of the major autoantigens in autoimmune diabetes and is found in the insulin-producing beta cells of the pancreas. It is an important target when the immune system attacks the beta cells in autoimmune diabetes. The Antigen Based Therapy Diamyd® is a GAD-based diabetes vaccine aiming to induce tolerance to GAD, thereby intervening in the autoimmune attack and preserving the capacity to produce insulin in patients with autoimmune diabetes, e.g. type 1 diabetes and LADA.

Investigator-Initiated Trials

Diamyd Medical’s GMP manufactured clinical study drug Diamyd® has been approved for several clinical trials in children and is available for investigator-initiated trials conducted by academia and industry.